Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Go back to Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
Johnson & Johnson (NYSE: JNJ) Delayed: 275.23 -3.2 (1.15%)
Previous Close $278.43    52 Week High $126.07 
Open $275.13    52 Week Low $94.28 
Day High $277.80    P/E 57.22 
Day Low $274.75    EPS $4.81 
Volume 4,320,320